Member Info for BertieBassett

I have lived in Japan and seen first hand how the corporate operation works ... I would find it rather odd for a Japanese company to moot a deal and then follow through as it would show a huge loss of face ... I cannot think of a Japanese company that has done a volte-face ... Just a thought -- BB --

B****r, b*****s, etc etc ...

Conviviality Plc ("Conviviality", the "Company" or the "Group") Update on Fundraising On 21 March 2018, the Company provided an update to the market on the actions the Board were undertaking to resolve the Company's funding requirements. A key element to this was an equity placing to raise gross proceeds of �125.0 million (the "Placing"), which the Directors believe is the minimum amount required to adequately recapitalise the business. Despite a significant number of meetings with potential investors resulting in good levels of demand, and constructive discussions with a number of key customers and suppliers regarding the provision of support, there was ultimately insufficient demand to raise the full �125.0 million. The Board wish to thank its customers, suppliers and employees for their continued support during this difficult period for the Company. The Company is in discussions with its lending banks and advisors regarding other possible options and is in receipt of a number of inbound enquiries regarding a potential sale of all or parts the business. A further update will be made as appropriate. The Board believe that shareholders in the Company will receive little-to-nil value.

28th March 2018 Statement re press speculation The Board of NEX Group plc ("NEX") notes this afternoon's press speculation and confirms that it has received a non-binding proposal from CME Group Inc. ("CME") regarding a potential acquisition of NEX at a price of �10 per share. Discussions are at an advanced stage; there can be no certainty that an offer for NEX will be made, nor as to the terms of any offer. A further announcement will be made if appropriate. In accordance with Rule 2.6(a) of the Code, CME must, by not later than 5.00 pm on 12th April 2018, either announce a firm intention to make an offer for NEX in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer for NEX, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Panel on Takeovers and Mergers in accordance with Rule 2.6(c) of the Code. This announcement has been made without the consent of CME. In accordance with Rule 26.1 of the Code, a copy of this announcement will be available on NEX's website (http://www.nex.com/investors/possible-offer) by no later than 12 noon (London time) on the business day following the date of this announcement. The content of the website referred to in this announcement is not incorporated into, and does not form part of, this announcement.

Takeda Pharm Co Ltd Rule 8 Announcement to Shareholders RNS Number : 3110J Takeda Pharmaceutical Company Ltd 28 March 2018 28 March 2018 Takeda Pharmaceutical Company Limited Notice to Shareholders Regarding UK Takeover Code Disclosure Requirements On 28 March 2018, Takeda Pharmaceutical Company Limited ("Takeda") made an announcement regarding a possible offer by Takeda for Shire plc ("Shire") (the "Possible Offer"). Takeda wishes to direct the attention of its shareholders to certain disclosure requirements applicable to the Possible Offer. The relevant disclosure requirements are set out in Rule 8 of the UK City Code on Takeovers and Mergers, which is published and administered by the UK Takeover Panel. In particular, Rule 8.3 of the Takeover Code requires that any person who is interested (directly and/or indirectly) in 1% or more of any class of relevant security of any party to the possible offer must make (a) an Opening Position Disclosure and (b) a Dealing Disclosure if they deal in any relevant security of any party to the possible offer during an offer period. Takeda's ordinary shares are relevant securities for the purposes of this offer period. Full details are set out at the end of this announcement. Further information about the Takeover Panel's disclosure regime is available at: http://www.thetakeoverpanel.org.uk/disclosure. If any Takeda shareholder has any questions on these disclosure requirements, the Takeover Panel's Market Surveillance Unit will be happy to answer them and should be contacted on +44 (0)20 7638 0129. No Offer or Solicitation This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. In particular, no offer of securities shall be made in the United States absent registration under the US Securities Act of 1933, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the US Securities Act of 1933. Disclosure requirements of the Code Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to

oh me oh my ... :(

ALSO - the prize is AUD1 billion ... !

okay .. but it was i think 28 or 30c a share when the plan was announced .. so surely priced in? -- BB --

why would someone say it's failed and then not produce any evidence to back up that incendiary statement? now, that is a fail ... -- BB --

i know! seems a wee odd ... saying the share is worth between 47 to 55 ... and the share price is 37.5 ... um .. 20% uplift?

i see where you are coming from ... i am tempted too ... the main question is the fund raise ... BUT ... Stel have been lent AUD3 million - no strings attached - so NWF must feel comfortable with the raise. The new mine is being valued at over AUD 1 BILLION .. so 30 mill seems quite achievable ... as ever. DYOR ... -- BB --

there are also money-making shares eg ACRL for the "now" that are being plundered. with this share not moving, it seems prudent to play away and come back ...

i think that until the AUD30 million fund raise is officially announced then we will not see madness here ... but I think it's coming! :)

as have i !!

http://www.cityam.com/282895/drinks-giant-ab-inbev-urges-shareholders-support let's hope so!

http://www.cityam.com/282895/drinks-giant-ab-inbev-urges-shareholders-support let's hope so!

Hmmm ... no RNS on LSE but an 0700 on Investegate ... A step closer to a cure for flu. No-one seems interested! Why? -- BB --

hVIVO plc Initial results from a Phase IIb study of FLU-v RNS Number : 8407I hVIVO plc 26 March 2018 For immediate release 7.00am: 26 March 2018 HVIVO PLC ("hVIVO" or the "Company") hVIVO announces initial results from a Phase IIb study of FLU-v, a first-in-class universal flu vaccine candidate hVIVO plc (AIM: HVO) today announces encouraging initial results from a Phase IIb study examining FLU-v as a potential universal vaccine against influenza (flu). Preliminary analysis of the primary endpoint revealed a trend to statistical significance, with further testing of samples ongoing that could affect the final outcome. In addition, the study demonstrated a statistically significant reduction in overt flu symptoms in treated subjects in one arm of the trial (p=.02). Importantly, this vaccine candidate is designed to minimise the impact of the virus by reducing symptoms - potentially relegating flu to a much milder disease - through stimulating an immune response mediated through T-cells, in contrast to seasonal flu vaccines, that prevent infection through antibody protection. The Company believe this is the first time that any universal flu vaccine candidate has demonstrated a statistically significant reduction in a symptom measure for flu in humans in a controlled clinical study. FLU-v is being developed by Imutex Limited, hVIVO's 49% joint venture with PepTcell Limited, trading as the SEEK Group ("SEEK"). The FLU-v Challenge Study The FLU-v Phase IIb flu challenge study (ClinicalTrials.gov Identifier: NCT03180801) was part of the collaboration between PepTcell Limited and the National Institute of Allergy and Infectious Diseases, part of the US National Institute of Health (NIH). In this double-blind placebo-controlled single-site study, conducted at hVIVO's quarantine facilities, 123 volunteers were randomised to one of two FLU-v plus adjuvant dosing regimen arms1 or a placebo plus adjuvant arm. Given the novel putative mechanism of action of FLU-v, the study employed a panel of study endpoints allowing the Company and the NIH to explore broadly the most relevant efficacy endpoints for future clinical development. These included composite endpoints involving symptom scores and lab-determined biomarkers, such as viral load, as well as symptom-based endpoints that are suited to FLU-v's mechanism of action. The primary endpoint, a novel composite score combining the occurrence of one symptom of flu-like illness and changes in viral load, trended to statistical significance in the single FLU-v dose arm versus placebo when using qPCR to determine viral load. The NIH is currently independently evaluating, as a prespecified part of this study, this primary endpoint using the more multifaceted Luminex platform (the platform on which the study powering was derived) to determine viral load. Results of these tests could impact the final result. This data will

MM - yes - um - would look to make an excuse here eg it was early etc but no, i just got excited about Glen and RRS in a room together! :)

Telegraph the new code was “an over-enthusiastic attempt to harvest the taxes without thinking of the importance of longer-term investment”. “You can’t expect us to continue to invest in a country that doesn’t respect its own laws,” he said.